Trial Profile

A Phase 2 study of POLB 001 for to treat and prevent cancer immunotherapy-induced CRS

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 07 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs POLB 001 (Primary)
Indications Cytokine release syndrome
Focus Therapeutic Use

Most Recent Events

02 Jan 2025 According to a Poolbeg Pharma media release, topline data expected in the second half of 2026.
22 Jan 2024 New trial record
17 Jan 2024 According to a Poolbeg Pharma media release, results data from from the recent LPS human challenge trial, support the companys strategic expansion of the Phase II ready POLB 001 to treat and prevent cancer immunotherapy-induced CRS.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com